Health

STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 25/09/2026, 18:36:24 UTC.

Briefings

A U.N.-backed agency signed sub-licensing deals with 11 manufacturers to develop generic versions of Roche's Xofluza for pandemic preparedness. Brokered by the Medicines Patent Pool, the agreements allow companies to manufacture and supply the drug in 129 countries, including nearly all low- and middle-income nations. Manufacturers receive technical data and regulatory support to help achieve this goal.

Key points

• The U.N.-backed agency signed sub-licensing deals with 11 manufacturers to develop generic versions of Roche's Xofluza for pandemic preparedness.
• The agreements allow companies to manufacture and supply the drug in 129 countries, covering nearly all low- and middle-income nations.

Context and limitations

The evidence covers the signing of sub-licensing deals by a U.N.-backed agency in 2026. Coverage is limited to the specific agreements and does not include details on the actual manufacturing timeline, regulatory approval outcomes, or the financial impact on manufacturers.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/09/2026, 23:05:47 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicqqz572i27hlvexsrvhiag42g32oqtqqq5jq2gvvki5kwl2qw7i4